+

WO2006010498A3 - Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2) - Google Patents

Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2) Download PDF

Info

Publication number
WO2006010498A3
WO2006010498A3 PCT/EP2005/007707 EP2005007707W WO2006010498A3 WO 2006010498 A3 WO2006010498 A3 WO 2006010498A3 EP 2005007707 W EP2005007707 W EP 2005007707W WO 2006010498 A3 WO2006010498 A3 WO 2006010498A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
metap2
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2005/007707
Other languages
French (fr)
Other versions
WO2006010498A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2006010498A2 publication Critical patent/WO2006010498A2/en
Publication of WO2006010498A3 publication Critical patent/WO2006010498A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/11—Aminopeptidases (3.4.11)
    • C12Y304/11018—Methionyl aminopeptidase (3.4.11.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human MetAP2 which is associated with the cardiovascular diseases, infections, respiratory diseases, gastroenterological diseases, cancer, metabolic diseases, inflammations, hematological diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, respiratory diseases, gastroenterological diseases, cancer, metabolic diseases, inflammations, hematological diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of MetAP2 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/007707 2004-07-28 2005-07-15 Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2) WO2006010498A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017833 2004-07-28
EP04017833.7 2004-07-28

Publications (2)

Publication Number Publication Date
WO2006010498A2 WO2006010498A2 (en) 2006-02-02
WO2006010498A3 true WO2006010498A3 (en) 2006-06-22

Family

ID=34981850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007707 WO2006010498A2 (en) 2004-07-28 2005-07-15 Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2)

Country Status (1)

Country Link
WO (1) WO2006010498A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254843A1 (en) * 2006-04-18 2007-11-01 Praecis Pharmaceuticals Incorporated Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors
WO2008066641A2 (en) * 2006-11-06 2008-06-05 Praecis Pharmaceuticals Incorporated Methods for treating mitf associated diseases by the use of methionine aminopeptidase-2 inhibitors
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
WO2011085198A1 (en) * 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
BR112014028041A2 (en) 2012-05-08 2017-06-27 Zafgen Inc treatment of hypothalamic obesity with metap2 inhibitors
CA2873574A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumagillol type compounds and methods of making and using same
KR20150126924A (en) * 2013-03-14 2015-11-13 자프겐 인크. Methods of treating renal disease and other disorders
CN106432255A (en) 2015-08-11 2017-02-22 扎夫根公司 Fumigillol spiro-compound, preparation and use method thereof
AR105671A1 (en) 2015-08-11 2017-10-25 Zafgen Inc HUMEROCYCLIC COMPOUNDS OF FUMAGILLOL AND ITS METHODS OF ELABORATION AND USE

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
US5888796A (en) * 1996-01-31 1999-03-30 St. Louis University Clone of a nucleotide sequence encoding a protein having two functions
US6136604A (en) * 1999-10-27 2000-10-24 Isis Pharmaceuticals Inc. Antisense inhibition of methionine aminopeptidase 2 expression
WO2001075177A2 (en) * 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tumor markers in ovarian cancer
US20020182701A1 (en) * 2001-08-30 2002-12-05 Saint Louis University Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof
US6638750B1 (en) * 1999-03-11 2003-10-28 Pharmacia Corporation Methionine aminopeptidase type 3
US20030203406A1 (en) * 1999-03-11 2003-10-30 Sympson Carolyn J. Human methionine aminopeptidase type 3
US20030204070A1 (en) * 2002-01-23 2003-10-30 Jian Chen Polynucleotide encoding a novel methionine aminopeptidase, protease-39
WO2004092413A2 (en) * 2003-04-18 2004-10-28 Novartis Ag High throughput functional genomic screening methods for osteoarthritis
WO2005016962A2 (en) * 2003-08-11 2005-02-24 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888796A (en) * 1996-01-31 1999-03-30 St. Louis University Clone of a nucleotide sequence encoding a protein having two functions
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
US20010034455A1 (en) * 1997-06-09 2001-10-25 Liu Jun O. Type 2 methionine aminopeptidase (MetAP2) inhibitors and uses thereof
US6638750B1 (en) * 1999-03-11 2003-10-28 Pharmacia Corporation Methionine aminopeptidase type 3
US20030203406A1 (en) * 1999-03-11 2003-10-30 Sympson Carolyn J. Human methionine aminopeptidase type 3
US6136604A (en) * 1999-10-27 2000-10-24 Isis Pharmaceuticals Inc. Antisense inhibition of methionine aminopeptidase 2 expression
WO2001075177A2 (en) * 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tumor markers in ovarian cancer
US20020182701A1 (en) * 2001-08-30 2002-12-05 Saint Louis University Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof
US20030204070A1 (en) * 2002-01-23 2003-10-30 Jian Chen Polynucleotide encoding a novel methionine aminopeptidase, protease-39
WO2004092413A2 (en) * 2003-04-18 2004-10-28 Novartis Ag High throughput functional genomic screening methods for osteoarthritis
WO2005016962A2 (en) * 2003-08-11 2005-02-24 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Also Published As

Publication number Publication date
WO2006010498A2 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2006010498A3 (en) Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005100990A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2006010494A3 (en) Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 1 (metapi)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2006013012A3 (en) Diagnostics and therapeutics for diseases associated with napsin 1 (nap1)
WO2006013015A3 (en) Diagnostics and therapeutics for diseases associated with marapsin (mpn)
WO2005026719A3 (en) Diagnostics and therapeutics for diseases associated with transporter slc22a3 (slc22a3)
WO2005100997A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
WO2006010497A3 (en) Diagnostics and therapeutics for diseases associated with choline kinase (chk)
WO2006005470A3 (en) Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge)
WO2005101009A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2)
WO2006010495A3 (en) Diagnostics and therapeutics for diseases associated with carboxypeptidase a3 (cpa3)
WO2005052586A3 (en) Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 3 (kcnk3)
WO2005119263A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92)
WO2005113788A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
WO2006010489A3 (en) Diagnostics and therapeutics for diseases associated with choline kinase like protein (chkl)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载